Dexrazoxane for the prevention of cardiomyopathy in anthracycline treated pediatric cancer patients

Pediatric Blood and Cancer

Volumn 44, Issue 7, 2005, Pages 584-588

  Anderson, Barry ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Anthracycline; Cardiotoxicity; Dexrazoxane

Indexed keywords

ANTHRACYCLINE ANTIBIOTIC AGENT; BLEOMYCIN; CISPLATIN; CYCLOPHOSPHAMIDE; DAUNORUBICIN; DOXORUBICIN; ETOPOSIDE; FLUOROURACIL; METHOTREXATE; PREDNISONE; RAZOXANE; VINCRISTINE;

ACUTE LYMPHOCYTIC LEUKEMIA; ADOLESCENT; ANTINEOPLASTIC ACTIVITY; BREAST CANCER; CANCER CHEMOTHERAPY; CARDIOMYOPATHY; CARDIOTOXICITY; CHILD; CHILDHOOD CANCER; CLINICAL TRIAL; CONFERENCE PAPER; CONGESTIVE HEART FAILURE; HEART PROTECTION; HODGKIN DISEASE; HUMAN; IRON CHELATION; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; SARCOMA; TOXICITY; TREATMENT OUTCOME;

ANTHRACYCLINES; ANTIBIOTICS, ANTINEOPLASTIC; CARDIOMYOPATHIES; CARDIOVASCULAR AGENTS; CHILD; HUMANS; NEOPLASMS; RAZOXANE;

EID: 18244363848     PISSN: 15455009     EISSN: None     Source Type: Journal    
DOI: 10.1002/pbc.20358     Document Type: Conference Paper

References (23)

1. Krischer J, Epstein S, Cuthbertson D, et al. Clinical cardiotoxicity following anthracycline treatment for childhood cancer: The Pediatric Oncology Group experience. J Clin Oncol 1997;15: 1544-1552.
2. Lipshultz SE, Colan SD, Gelber RD, et al. Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood. N Engl J Med 1997;324:808-815.
3. Steinherz L, Steinherz P. Delayed cardiac toxicity from anthracycline therapy. Pediatrician 1991;18:49-52.
4. Sorensen K, Levitt G, Bull C, et al. Anthracycline dose in childhood acute lymphoblastic leukemia: Issues of early survival versus late cardiotoxicity. J Clin Oncol 1997;15:61-68.
5. Sorensen K, Levitt GA, Bull C, et al. Late anthracycline cardiotoxicity after childhood cancer: A prospective longitudinal study. Cancer 2003;97:1991-1998.
6. Ewer MS, Jaffe N, Ried H, et al. Doxorubicin cardiotoxicity in children: Comparison of a consecutive divided daily dose administration schedule with single dose (rapid) infusion administration. Med Pediatr Oncol 1998;31:512-515.
7. Lipshultz SE, Giantris AL, Lipsitz SR, et al. Doxorubicin administration by continuous infusion is not cardioprotective: The Dana-Farber 91-01 Acute Lymphoblastic Leukemia protocol. J Clin Oncol 2002;20:1677-1682.
8. Gupta M, Steinherz PG, Cheung NK, et al. Late cardiotoxicity after bolus versus infusion anthracycline therapy for childhood cancers. Med Pediatr Oncol 2003;40:343-347.
9. Levitt GA, Dorup I, Sorensen K, et al. Does anthracycline administration by infusion in children affect late cardiotoxicity? Br J Haematol 2004;124:463-468.
10. Meyer C. The role of iron in doxorubicin-induced cardiomyopathy. Sem Oncol 1998;25;Suppl 10:10-14.
11. Speyer J, Wasserheit C. Strategies for reduction of anthracycline cardiac toxicity. Sem Oncol 1998;25:525-537.
12. Swain SM, Whaley FS, Gerber MC, et al. Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer. J Clin Oncol 1997;15:1318-1332.
13. Swain SM, Whaley FS, Gerber MC, et al. Delayed administration of dexrazoxane provides cardioprotection for patients with advanced breast cancer treated with doxorubicin-containing therapy. J Clin Oncol 1997;15:1333-1340.
14. Swain SM, Vici P. The current and future role of dexrazoxane as a cardioprotectant in anthracycline treatment: Expert panel review. J Cancer Res Clin Oncol 2004;130:1-7.
15. Schuchter LM, Hensley ML, Meropol NJ, et al. 2002. Update of recommendations for the use of chemotherapy and radiotherapy protectants: Clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol 2002;20:2895-2903.
16. Bu'Lock FA, Gabriel HM, Oakhill A, et al. Cardioprotection by ICRF187 against high dose anthracycline toxicity in children with malignant disease. Br Heart J 1993;70:185-188.
17. Schiavetti A, Castello MA, Versacci P, et al. Use of ICRF-187 for prevention of anthracycline cardiotoxicity in children: Preliminary results. Pediatr Hematol Oncol 1997;14:213-222.
18. Wexler LH, Andrich MP, Venzon D, et al. Randomized trial of the cardioprotective agent ICRF-187 in pediatric sarcoma patients treated with doxorubicin. J Clin Oncol 1996;14:362-372.
19. Schwartz C, Tebbi C, London W, et al. Enhanced toxicity in pediatric Hodgkin Disease (HD) patients treated with DBVE or DBVE-PC and Dexrazoxane (DXR). Blood 2003;102:493.
20. Schwartz C, Wexler LH, Devidas M, et al. P9754 therapeutic intensification in non-metastatic osteosarcoma: A COG trial. Am Soc Clin Oncol 2004; Abstract no. 8514.
21. Lipshultz SE, Rifai N, Dalton VM, et al. The effect of dexrazoxane on myocardial injury in doxorubicin-treated children with acute lymphoblastic leukemia. N Engl J Med 2004;351:145-153.
22. Lipshultz S, Lipsitz S, Mone S. Female sex and higher drug dose as risk factors for late cardiotoxic effects of doxorubicin therapy for childhood cancer. N Engl J Med 1995;332:1738-1743.
23. Holcenberg JS, Tutsch KD, Earhart RH, et al. Phase I study of ICRF-187 in pediatric cancer patients and comparison of its pharmacokinetics in children and adults. Cancer Treat Rep 1986; 70:703-709.